Literature DB >> 28174068

Patient and caregiver reactions to clinical amyloid imaging.

Joshua D Grill1, Chelsea G Cox2, Sarah Kremen3, Mario F Mendez4, Edmond Teng4, Jill Shapira4, John M Ringman5, Liana G Apostolova6.   

Abstract

INTRODUCTION: Amyloid imaging is a tool that has recently become available to dementia specialists evaluating patients with possible Alzheimer's disease. Studies have assessed the impact of amyloid imaging on diagnostic and treatment decisions, but patient and family perspectives have received less attention.
METHODS: To examine how amyloid imaging affects the diagnostic experience of patients and families, we interviewed members of 26 patient-caregiver dyads with whom a neurologist discussed the option of amyloid positron emission tomography.
RESULTS: Most participants who chose to undergo amyloid imaging would choose to do so again. Regardless of the scan outcome, patients and caregivers commonly expressed relief on learning the scan results. Some participants expressed expectations that were beyond scan capabilities. DISCUSSION: Amyloid imaging may provide information that patients and their families find useful. Clinicians must set correct expectations and ensure that families understand the limitations of amyloid imaging.
Copyright © 2017 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Amyloid imaging; Biomarker; Diagnosis; Encounter; Positron emission tomography

Mesh:

Substances:

Year:  2017        PMID: 28174068      PMCID: PMC5544590          DOI: 10.1016/j.jalz.2017.01.001

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  38 in total

1.  Clinical amyloid imaging in logopenic progressive aphasia.

Authors:  Mario F Mendez; Valeriy Sabodash
Journal:  Alzheimer Dis Assoc Disord       Date:  2015 Jan-Mar       Impact factor: 2.703

2.  Alzheimer's imaging agents struggle to find a market outside trials.

Authors:  Sarah C P Williams
Journal:  Nat Med       Date:  2013-12       Impact factor: 53.440

3.  Impact of beta-amyloid-specific florbetaben PET imaging on confidence in early diagnosis of Alzheimer's disease.

Authors:  C G Schipke; O Peters; I Heuser; T Grimmer; M N Sabbagh; O Sabri; C Hock; M Kunz; J Kuhlmann; C Reininger; M Blankenburg
Journal:  Dement Geriatr Cogn Disord       Date:  2012-07-20       Impact factor: 2.959

4.  Making sense of nonsense: experiences of mild cognitive impairment.

Authors:  Renée L Beard; Tara M Neary
Journal:  Sociol Health Illn       Date:  2012-05-03

5.  Amyloid negativity in patients with clinically diagnosed Alzheimer disease and MCI.

Authors:  Susan M Landau; Andy Horng; Allison Fero; William J Jagust
Journal:  Neurology       Date:  2016-03-11       Impact factor: 9.910

6.  Estimating and communicating prognosis in advanced neurologic disease.

Authors:  Robert G Holloway; Robert Gramling; Adam G Kelly
Journal:  Neurology       Date:  2013-02-19       Impact factor: 9.910

7.  Impact of ¹⁸F-florbetapir PET imaging of β-amyloid neuritic plaque density on clinical decision-making.

Authors:  Anthony S Zannas; P Murali Doraiswamy; Katie S Shpanskaya; Kelly R Murphy; Jeffrey R Petrella; James R Burke; Terence Z Wong
Journal:  Neurocase       Date:  2013-05-14       Impact factor: 0.881

8.  Using AD biomarker research results for clinical care: a survey of ADNI investigators.

Authors:  Melanie B Shulman; Kristin Harkins; Robert C Green; Jason Karlawish
Journal:  Neurology       Date:  2013-08-21       Impact factor: 9.910

9.  Confidentiality in preclinical Alzheimer disease studies: when research and medical records meet.

Authors:  Jalayne J Arias; Jason Karlawish
Journal:  Neurology       Date:  2014-01-29       Impact factor: 9.910

10.  Reaction to a dementia diagnosis in individuals with Alzheimer's disease and mild cognitive impairment.

Authors:  Brian D Carpenter; Chengjie Xiong; Emily K Porensky; Monica M Lee; Patrick J Brown; Mary Coats; David Johnson; John C Morris
Journal:  J Am Geriatr Soc       Date:  2008-01-05       Impact factor: 5.562

View more
  15 in total

1.  A Preliminary Study of Clinical Trial Enrollment Decisions Among People With Mild Cognitive Impairment and Their Study Partners.

Authors:  Chelsea G Cox; Mary M Ryan B A; Daniel L Gillen; Joshua D Grill
Journal:  Am J Geriatr Psychiatry       Date:  2018-11-03       Impact factor: 4.105

2.  Patient Stakeholder Versus Physician Preferences Regarding Amyloid PET Testing.

Authors:  Melissa J Armstrong; Gary S Gronseth; Gregory S Day; Carol Rheaume; Slande Alliance; C D Mullins
Journal:  Alzheimer Dis Assoc Disord       Date:  2019 Jul-Sep       Impact factor: 2.703

3.  The Effects and Meanings of Receiving a Diagnosis of Mild Cognitive Impairment or Alzheimer's Disease When One Lives Alone.

Authors:  Elena Portacolone; Julene K Johnson; Kenneth E Covinsky; Jodi Halpern; Robert L Rubinstein
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

Review 4.  Ethical Considerations in Communicating Alzheimer's Disease Neuroimaging Biomarker Test Results to Symptomatic Individuals.

Authors:  Daniel A Wilkenfeld; Staci L Orbell; Jennifer H Lingler
Journal:  Neurotherapeutics       Date:  2021-04-15       Impact factor: 7.620

5.  Letter.

Authors:  Ara S Khachaturian
Journal:  Alzheimers Dement (Amst)       Date:  2017-11-21

Review 6.  Communicating mild cognitive impairment diagnoses with and without amyloid imaging.

Authors:  Joshua D Grill; Liana G Apostolova; Szofia Bullain; Jeffrey M Burns; Chelsea G Cox; Malcolm Dick; Dean Hartley; Claudia Kawas; Sarah Kremen; Jennifer Lingler; Oscar L Lopez; Mark Mapstone; Aimee Pierce; Gil Rabinovici; J Scott Roberts; Seyed Ahmad Sajjadi; Edmond Teng; Jason Karlawish
Journal:  Alzheimers Res Ther       Date:  2017-05-04       Impact factor: 6.982

7.  Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review.

Authors:  Arno de Wilde; Marieke M van Buchem; René H J Otten; Femke Bouwman; Andrew Stephens; Frederik Barkhof; Philip Scheltens; Wiesje M van der Flier
Journal:  Alzheimers Res Ther       Date:  2018-07-28       Impact factor: 6.982

8.  Family members' perspectives on learning cognitively unimpaired older adults' amyloid-β PET scan results.

Authors:  Emily A Largent; Maramawit Abera; Kristin Harkins; Sara J Feldman; Wendy R Uhlmann; J Scott Roberts; Jason Karlawish
Journal:  J Am Geriatr Soc       Date:  2021-07-12       Impact factor: 5.562

9.  Amnestic MCI patients' experiences after disclosure of their amyloid PET result in a research context.

Authors:  Gwendolien Vanderschaeghe; Jolien Schaeverbeke; Rose Bruffaerts; Rik Vandenberghe; Kris Dierickx
Journal:  Alzheimers Res Ther       Date:  2017-12-02       Impact factor: 6.982

10.  Addressing ethical challenges of disclosure in dementia prediction: limitations of current guidelines and suggestions to proceed.

Authors:  Zümrüt Alpinar-Sencan; Silke Schicktanz
Journal:  BMC Med Ethics       Date:  2020-05-11       Impact factor: 2.652

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.